The latest price target for Elicio Therapeutics (NASDAQ:ELTX) was reported by Jones Trading on October 31, 2024. The analyst firm set a price target for $9.00 expecting ELTX to rise to within 12 months (a possible 57.89% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Elicio Therapeutics (NASDAQ:ELTX) was provided by Jones Trading, and Elicio Therapeutics initiated their buy rating.

There is no last upgrade for Elicio Therapeutics

There is no last downgrade for Elicio Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elicio Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elicio Therapeutics was filed on October 31, 2024 so you should expect the next rating to be made available sometime around October 31, 2025.

While ratings are subjective and will change, the latest Elicio Therapeutics (ELTX) rating was a initiated with a price target of $0.00 to $9.00. The current price Elicio Therapeutics (ELTX) is trading at is $5.70, which is within the analyst’s predicted range.